Who are OPC-6535's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GW406381, GW685698, OPC-6535 Tablets (drug).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/opc-6535.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

OPC-6535 — Competitive Intelligence Brief

OPC-6535 (OPC-6535) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2X7 receptor antagonist. Area: Neurology / Pain.

phase 3 P2X7 receptor antagonist P2X7 Neurology / Pain Small molecule Live · refreshed every 30 min

Target snapshot

OPC-6535 (OPC-6535) — Otsuka Pharmaceutical Co., Ltd.. OPC-6535 is a selective antagonist of the P2X7 receptor, which modulates purinergic signaling involved in inflammatory and immune responses.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OPC-6535 TARGET	OPC-6535	Otsuka Pharmaceutical Co., Ltd.	phase 3	P2X7 receptor antagonist	P2X7
GW406381	GW406381	GlaxoSmithKline	phase 3	P2X7 receptor antagonist	P2X7
GW685698	GW685698	GlaxoSmithKline	phase 3	P2X7 receptor antagonist	P2X7
OPC-6535 Tablets (drug)	OPC-6535 Tablets (drug)	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	P2X7 receptor antagonist	P2X7

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2X7 receptor antagonist class)

GlaxoSmithKline · 2 drugs in this class
Akros Pharma Inc. · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OPC-6535 — Competitive Intelligence Brief. https://druglandscape.com/ci/opc-6535. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab